PubMed · 1349950
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P C Hannaford, C R Kay. 1992-05-16. After ISIS-3.. https://pubmed.ncbi.nlm.nih.gov/1349950/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The relative efficacy and safety of individual thrombolytic agents, administered alone and with antiplatelet and antithrombotic drugs, in the treatment of acute myocardial infarction are presented. The clinical benefits and risks of treatment choices are discussed in relation to the mechanisms of the formation and prevention of thrombus and thrombolysis. It is concluded that streptokinase, tissue plasminogen activator (t-PA), and anisoylated plasminogen-streptokinase activator complex (APSAC) significantly reduce mortality and improve left ventricular function equally, despite differences in the rate at which they achieve vascular patency, their durations of action, and the extent to which their use is associated with adverse events. The questions of how best to minimize reocclusion/reinfarction, bleeding, and stroke are discussed, with particular focus on the beneficial use of aspirin and the unresolved issue of how best to use heparin.
Explore the source record for details and available documents.
Explore the source record for details and available documents.